Clinical trial
LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus
NCT00349986 · Sanofi, Industry · Terminated
Key facts
| NCT number | NCT00349986 |
|---|---|
| Title | LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus |
| Official title | The Determination of the First Dose and the Optimal Time of Administration of Insulin Glargine Combined With Oral Antidiabetic Drug in Poorly Controlled Type II Diabetic Patients |
| Lead sponsor | Sanofi, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Insuline glargine |
| Enrollment | 4 |
| Start date | Sep 1, 2006 |
| Primary completion | Jun 1, 2007 |
| First posted | Jul 10, 2006 |
| Last update posted | Dec 7, 2009 |
| Countries | Hungary |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: